可编程器件为多种应用提供强大驱动力

几年前,超过半数的半导体消费均归功于企业用户,而如今,普通消费者已成为推动这一消费增长的主要推动力.从手机到电视,从计算机到汽车,普通消费者在半导体领域的需求占主导地位,市场竞争也比以往任何时候都更为激烈,成功与否取决于能否推出独树一帜的产品,而价格则是最重要的决定性因素.对系统制造商而言,这意味着必须展开激烈的市场"拼杀",而产品的生命周期则日益缩短.与此同时,市场细分进一步明显,过去的大规模市场被细分为更为狭窄的市场领域,只有提供具有各种不同特性、功能和地域特征的产品才能充分满足客户的特定需求.     

65nm半导体工艺发展策略

本文研究Altera在65nm工艺上的工程策略,介绍公司如何为客户降低生产和计划风险,并同时从根本上提高密度、性能,及降低成本和功耗.     

Chemically-speciated on-road PM2.5 motor vehicle emission factors in Hong Kong

PM_2.5 (particle with an aerodynamic diameter less than 2.5 µm) was measured in different microenvironments of Hong Kong (including one urban tunnel, one Hong Kong/Mainland boundary roadside site, two urban roadside sites, and one urban ambient site) in 2003. The concentrations of organic carbon (OC), elemental carbon (EC), water-soluble ions, and up to 40 elements (Na to U) were determined. The average PM_2.5 mass concentrations were 229 ± 90, 129 ± 95, 69 ± 12, 49 ± 18 µg m^− 3 in the urban tunnel, cross boundary roadside, urban roadside, and urban ambient environments, respectively. Carbonaceous particles (sum of organic material [OM] and EC) were the dominant constituents, on average, accounting for ∼ 82% of PM_2.5 emissions in the tunnel, ∼ 70% at the three roadside sites, and ∼ 48% at the ambient site, respectively. The OC/EC ratios were 0.6 ± 0.2 and 0.8 ± 0.1 at the tunnel and roadside sites, respectively, suggesting carbonaceous aerosols were mainly from vehicle exhausts. Higher OC/EC ratio (1.9 ± 0.7) occurred at the ambient site, indicating contributions from secondary organic aerosols. The PM_2.5 emission factor for on-road diesel-fueled vehicles in the urban area of Hong Kong was 257 ± 31 mg veh^− 1 km^− 1, with a composition of ∼ 51% EC, ∼ 26% OC, and ∼ 9% SO₄⁼. The other inorganic ions and elements made up ∼ 11% of the total PM_2.5 emissions. OC composed the largest fraction (∼ 51%) in gasoline and liquid petroleum gas (LPG) emissions, followed by EC (∼ 19%). Diesel engines showed higher emission rates than did gasoline and LPG engines for most pollutants, except for V, Br, Sb, and Ba.     

The molecular structure of green fluorescent protein

The crystal structure of recombinant wild-type green fluorescent protein (GFP) has been solved to a resolution of 1.9 A by multiwavelength anomalous dispersion phasing methods. The protein is in the shape of a cylinder, comprising 11 strands of beta-sheet with an alpha-helix inside and short helical segments on the ends of the cylinder. This motif, with beta-structure on the outside and alpha-helix on the inside, represents a new protein fold, which we have named the beta-can. Two protomers pack closely together to form a dimer in the crystal. The fluorophores are protected inside the cylinders, and their structures are consistent with the formation of aromatic systems made up of Tyr66 with reduction of its C alpha-C beta bond coupled with cyclization of the neighboring glycine and serine residues. The environment inside the cylinder explains the effects of many existing mutants of GFP and suggests specific side chains that could be modified to change the spectral properties of GFP. Furthermore, the identification of the dimer contacts may allow mutagenic control of the state of assembly of the protein.     

A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy

BB-10010 is a variant of the human form of macrophage inflammatory protein-1alpha (MIP-1alpha), which has been shown in mice to block the entry of hematopoietic stem cells into S-phase and to increase their self-renewal capacity during recovery from cytotoxic damage. Its use may constitute a novel approach for protecting the quality of the stem cell population and its capacity to regenerate after periods of cytotoxic treatment. Thirty patients with locally advanced or metastatic breast cancer were entered into the first randomized, parallel group controlled phase II study. This was designed to evaluate the potential myeloprotective effects of a 7-day regimen of BB-10010 administered to patients receiving six cycles of 5-fluorouracil (5-FU), adriamycin, and cyclophosphamide (FAC) chemotherapy. Patients were randomized, 10 receiving 100 microgram/kg BB-10010, 11 receiving 30 microgram/kg BB-10010, and nine control patients receiving no BB-10010. BB-10010 was well-tolerated in all patients with no severe adverse events related to the drug. Episodes of febrile neutropenia complicated only 4% of the treatment cycles and there was no difference in incidence between the treated and nontreated groups. Studies to assess the generation of progenitor cells in long-term bone marrow cultures were performed immediately preceding chemotherapy and at the end of six dosing cycles in 18 patients. Circulating neutrophils, platelets, CD 34(+) cells, and granulocyte/macrophage colony-forming cell (GM-CFC) levels were determined at serial time points in cycles 1, 3, and 6. The results showed similar hemoglobin and platelet kinetics in all three groups. On completion of the six treatment cycles, the average pretreatment neutrophil levels were reduced from 5.3 to 1.7 x 10(9)/L in the control patients and from 4.3 to 1.9 and 4.5 to 2.5 x 10(9)/L in the 30/100 microgram/kg BB-10010 groups, respectively. Relative to their pretreatment values, 50% of the patients receiving BB-10010 completed the treatment with neutrophil values significantly higher than any of the controls (P = .02). Mobilization of GM-CFC was enhanced by BB-10010 with an additional fivefold increase over that generated by chemotherapy alone, giving a maximal 25-fold increase over pretreatment values. Bone marrow progenitor assays before and after this standard regimen of chemotherapy indicated little long-term cumulative impairment to recovery from chemotherapy. Despite the limited cumulative damage to the bone marrow, which may have minimized the protective value of BB-10010 during this regimen of chemotherapy, better recovery of neutrophils in the later treatment cycles with BB-10010 was indicated in a number of patients.     

Helicobacter pylori in South America

Interviews of a representative sample of 201 physicians (general practitioners, gynecologists, pediatricians) with a mean age of 47 years show: there is a unmanageable amount of information about drugs and their risks. The physicians prefer practical experience rather than specialized literature. As a result they plead for a central authority of information with periodical reports on the current knowledge of drug-therapy and with the possibility of therapeutical consultation.     

Human Mig chemokine: biochemical and functional characterization

Mig is a chemokine of the CXC subfamily that was discovered by differential screening of a cDNA library prepared from lymphokine-activated macrophages. The mig gene is inducible in macrophages and in other cells in response to interferon (IFN)-gamma. We have transfected Chinese hamster ovary (CHO) cells with cDNA encoding human Mig and we have derived CHO cell lines from which we have purified recombinant human Mig (rHuMig). rHuMig induced the transient elevation of [Ca2+]i in human tumor-infiltrating T lymphocytes (TIL) and in cultured, activated human peripheral blood-derived lymphocytes. No responses were seen in human neutrophils, monocytes, or Epstein-Barr virus-transformed B lymphoblastoid cell lines. rHuMig was chemotactic for TIL by a modified Boyden chamber assay but rHuMig was not chemotactic for neutrophils or monocytes. The CHO cell lines, IFN-gamma-treated human peripheral-blood monocytes, and IFN-gamma-treated cells of the human monocytic cell line THP-1 all secreted multiple and identical HuMig species as revealed by SDS-PAGE. Using the CHO-derived rHuMig, we have shown that the species' heterogeneity is due to proteolytic cleavage at basic carboxy-terminal residues, and that the proteolysis occurs before and not after rHuMig secretion by the CHO cells. The major species of secreted rHuMig ranged from 78 to 103 amino acids in length, the latter corresponding to the full-length secreted protein predicted from the HuMig cDNA. Carboxy-terminal-truncated forms of rHuMig were of lower specific activity compared to full-length rHuMig in the calcium flux assay, and the truncated species did not block the activity of the full-length species. It is likely that HuMig plays a role in T cell trafficking and perhaps in other aspects of the physiology of activated T cells.